Third you, thank Call. Thank Conference joining Penumbra's and afternoon, XXXX you Quarter for Jee. Good
quarter of for as third reported million, a currency. year-over-year total constant Our were XX.X% in revenues $XXX.X the XX.X% increase and
We had operating $XX.X quarter of $XX same an million period loss of income last for the in compared million the year. operating to
Our by innovate business robust markets. ability encouraged markets see to our continues and and within to we growth, our highly remain these patient
the but our to from In highlights the outperform contribution. our some the third in U.S., distributors. from was growth vascular and business growth in quarter, international the stronger business, international growth due quarter, to of the which we Reviewing significant significant saw of our orders drive continues timing
this it view introduced make difference opportunity. that believe be Over of growing area We for we a our come. the to will year, have we highly a years can attractive past patient where
To Indigo today, that clinical embolism. and results I our a will acute trial studying exciting pulmonary the positive System share from in end,
data Meeting, session were Just Vascular Akhilesh EXTRACT from Interventional represented Sista. VIVA at Advances a late-breaking Dr. the or by yesterday, at trial
to year. EXTRACT reminder, affects the Penumbra's PE roughly acute studying or enrolled pulmonary across XX patients study embolism a is Americans a As States. embolism. centers pulmonary single-arm Indigo The System United in XXX According XXX,XXX Association, American per trial, in Heart the
treated may interventionally. that believe XXX,XXX of someday these be We patients
major achieved EXTRACT of XX adverse within of in XX.X% are or treated estimate than rate those and technology. and reducing only the inadequate its event ratio currently that had The due XX% trial to we clinical X.X%. hours RV/LV endpoint primary less evidence by being today However, XX,XXX a
XX minutes. the patients the of and of of median Indigo XX.X% without procedure achieved time use were in was results These thrombolytics
the to Indigo EXTRACT potential to clearance trial, about We are FDA help from With more of who that suffer patients very regulatory encouraged for from by pursuing System PE. the and used Indigo we're be excited these results PE. results in
as effort will you another more. we opportunity know can We the timelines expand will on PE further thrombectomy. help opportunity for in be more We Penumbra's expected and keep believe that updated meaningful this countless Penumbra and to it peripheral patients
Our to excitement the and for continues System and succeed. continues our take Indigo necessary for tasks team the on are us to challenging work grow that to hard
opportunity. patient investors about we Our penetrating curious have are been how this
illustrate The We faces moment helps evidence. share have to I want how field story case a Indigo But talked surgeon use in decided our practice behind only but if embolectomy System we surgical quarter. and few an The work. ago, to take a the years case team in into this past clinical about brought vascular particular brief the his not would what Indigo involved did had this it innovation from it. he and handle in it
the this with to with A Due of XX and he System and patient clot the seconds leg. the team for like do was patient did elected old this burden team conversions his second physician the outcomes surprise, the Indigo and both this new fantastic to same commercial it large use work. few in legs. significant System clot evident months provide from the tubing the as a in positive thing motivation effort high-flow for Indigo and ENGINE patient tool, removed the frontline was and our unique difficult an leg new for like his our a the the this patient This enough requires circumstances, convert to on result him time To our ago, presented the the in and age to first physician XX-year to pump.
data, into will indication the all and and technology As support continued new we in innovation potential growth and move PE XXXX EXTRACT beyond, help vascular. our momentum
updates I neuro our on Now like two business. would provide to
our First, late technology, its latest a launched X JET FLEX. Since observed in launch, Penumbra stroke developments. XTRA we July, we few
of different Penumbra X JET FLEX the shared has been September, launch we prior have during in As launches. investor XTRA conferences than
the market quarter, competitive than U.S. longer just the have the the FLEX. customers X end of United of believe physician the about this that product. entering in we experience Given our JET the taken States it's Penumbra launches year, of current third number Through with prior half get meaningful to XTRA large products
the users Notwithstanding it well. has but speed navigation, been frame, outstanding. physicians the positive its from stroke feedback the increased been longer The feedback launches. overall positive any been only have And initial has the prior current been Physicians more as has favorable competitive catheter also of from time our about not from than ease-of-use customers, procedure. and of extremely
that to for particularly reduce devices allowing physicians the as near-term very early speaks JET is while and long-term unique Another impact for stent device. adjunctive observation our own positive need is strategy. Penumbra's some and XTRA our and/or is XD had to on such microcatheters, strength results, with product This X negative retrievers the of our financial clear FLEX some the this
Second, market following the six that said quarters quarter. as grew the stroke the at growth three a less U.S. linear market We have always in is straight sources rate we in suggest robust of that stroke quarter-by-quarter. that you market, growth seen U.S. measured not we've strong data recently remind third
with longer confidence as in strong market years, periods are us for of efforts have treat the and than ever, longer-term four great our coupled more to growth. past less historical as gives view lasted the still pattern the at two never that growth more outlook quarters. That Looking robust patients
support Along the now frontline to with aspiration our the gain evidence market, established intervention. our stroke will early share of longer-term been the in the in confidence has growth stroke of in as conviction. continue clinical mechanism The
& Just Diseases by an favor rates showed technique as in X was Xb X,XXX updated Cerebrovascular a of week, non-inferior physician Stroke better Association published measured patients to that meta-analysis, stroke. of evidence patient X XXXX. included aspiration X. and at retrievers. guidelines in over COMPASS last TICI And last treat we from or XXXX week, December September well. to versus This just the analysis as recommend stent stent of score This first-line mRS X, American And what numerical measured independent adds outcomes Journal or finally, is by its ASTER as to to as significant the higher revascularization retrievers initiated of statistically aspiration Heart XX to the learned trials days in
we're head FLEX newly our drive the X in our growth coming As business. innovation as in new into excited about XTRA well our launched neuro which will Penumbra JET as XXXX, we technology, stroke
While the markets, our United focus has initial underlying diseases States are global. patient the treat in our been for major we that both
several across address regulatory, Over with team to countries reimbursement in corresponding need with spent considerable the that be we our international challenges and see Asia. across opportunities commercial Europe and large capabilities We to months, past few successful. I've times
we the in as in in trends first, well years, results and stroke greater as have seen a business: financial Over and confidence of markets. in vast international gained the two few models we more we have patient variability last vascular; second, larger result our international as have distributor international opportunities seen our
While enter as many limitations quickly we grow. as us relationships to we structures such our distributor see our market, having have enabled of
working better support growth. evolve build to We long-term have to capabilities begun to structures our sustainable the
platform, develop future structures markets regulatory goals commercial and our in to portfolio remainder the to growth these and and leadership bring vascular in Our more stroke market, the have of geographies. our for and to portfolio neuro visibility a to these are have to continued
the prospects XXXX, confident growth of for end the many very for in the to future. move we As we are years durable about
the new We have innovating adding patients. by hard work products that done and continuously help
of date. we work, excited These now a We call place to reflection put, structures to in review the I'll but Sri that future. global Simply our about the turn the in we to can our now are so financials. over undertaking and are ever size success efforts more proper growth. than are our hard invest
